HBIO
What one share of Harvard Bioscience holds
Laboratory Analytical Instruments
Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development.
Harvard Bioscience’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $19.64 |
|---|---|
| Profit | −$2.33 |
| Capex (buildings and equipment) | $0.40 |
| Free cash flow | −$0.25 |
| Cash and investments | $1.43 |
| Debt | $8.06 |
| Book value | $1.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $28.64 | $2.42 | — | $5.51 | — | $25.38 |
| 2010 | $36.79 | $6.47 | — | $4.18 | — | $31.88 |
| 2011 | $36.51 | $1.28 | — | $2.23 | — | $33.46 |
| 2012 | $37.32 | $0.80 | — | $2.71 | — | $35.47 |
| 2013 | $32.95 | −$0.60 | — | $1.27 | — | $29.86 |
| 2014 | $32.69 | $0.71 | — | $1.31 | — | $29.32 |
| 2015 | $32.35 | −$5.67 | — | $0.21 | — | $22.84 |
| 2016 | $30.55 | −$1.30 | — | $1.57 | — | $20.62 |
| 2018 | $33.13 | −$0.80 | $0.27 | $0.52 | — | $22.13 |
| 2019 | $30.72 | −$1.20 | $0.32 | $1.81 | — | $21.39 |
| 2020 | $26.42 | −$2.02 | $0.30 | $2.12 | — | $19.46 |
| 2022 | $27.37 | −$2.30 | $0.38 | −$0.11 | — | $17.16 |
| 2023 | $26.46 | −$0.81 | $0.42 | $2.89 | — | $16.84 |
| 2024 | $21.62 | −$2.85 | $0.61 | −$0.28 | — | $14.37 |
| 2025 | $19.50 | −$12.77 | $0.28 | $1.23 | — | $3.07 |